Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eyepoint Inc (EYPT)

Eyepoint Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,188,821
  • Shares Outstanding, K 82,787
  • Annual Sales, $ 43,270 K
  • Annual Income, $ -130,870 K
  • EBIT $ -218 M
  • EBITDA $ -223 M
  • 60-Month Beta 1.76
  • Price/Sales 23.27
  • Price/Cash Flow N/A
  • Price/Book 6.17

Options Overview Details

View History
  • Implied Volatility 133.12% (-3.39%)
  • Historical Volatility 72.36%
  • IV Percentile 90%
  • IV Rank 47.93%
  • IV High 219.91% on 02/13/26
  • IV Low 53.23% on 07/30/25
  • Expected Move (DTE 1) 1.19 (8.23%)
  • Put/Call Vol Ratio 0.92
  • Today's Volume 5,969
  • Volume Avg (30-Day) 1,930
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 33,358
  • Open Int (30-Day) 25,421
  • Expected Range 13.27 to 15.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.78
  • Number of Estimates 3
  • High Estimate -0.71
  • Low Estimate -0.85
  • Prior Year -0.64
  • Growth Rate Est. (year over year) -21.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.11 +21.30%
on 02/04/26
16.73 -12.19%
on 01/23/26
-0.39 (-2.59%)
since 01/16/26
3-Month
12.11 +21.30%
on 02/04/26
19.11 -23.13%
on 12/08/25
+0.41 (+2.87%)
since 11/19/25
52-Week
3.91 +275.70%
on 04/09/25
19.11 -23.13%
on 12/08/25
+8.22 (+127.05%)
since 02/19/25

Most Recent Stories

More News
EyePoint Appoints Michael Campbell as Chief Commercial Officer

– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma – – Brings established track record of successful product launches and oversight...

EYPT : 14.40 (+0.28%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 14.40 (+0.28%)
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with...

EYPT : 14.40 (+0.28%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 14.40 (+0.28%)
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning...

EYPT : 14.40 (+0.28%)
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside

These biotech bets are only for investors who can stomach volatility.

EYPT : 14.40 (+0.28%)
IRD : 3.55 (-5.33%)
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with...

EYPT : 14.40 (+0.28%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 14.40 (+0.28%)
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU –...

EYPT : 14.40 (+0.28%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...

EYPT : 14.40 (+0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

EYEPOINT INC is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. EYEPOINT INC, formerly known as EyePoint Pharmaceuticals Inc., is based in WATERTOWN, Mass.

See More

Key Turning Points

3rd Resistance Point 16.26
2nd Resistance Point 15.73
1st Resistance Point 15.05
Last Price 14.40
1st Support Level 13.84
2nd Support Level 13.31
3rd Support Level 12.63

See More

52-Week High 19.11
Last Price 14.40
Fibonacci 61.8% 13.30
Fibonacci 50% 11.51
Fibonacci 38.2% 9.72
52-Week Low 3.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar